Oscar Health (NYSE:OSCR) Releases Earnings Results, Beats Estimates By $0.70 EPS

Oscar Health (NYSE:OSCR) issued its quarterly earnings data on Thursday. The company reported $1.10 EPS for the quarter, topping the consensus estimate of $0.40 by $0.70, FiscalAI reports. The company had revenue of $4.88 billion during the quarter, compared to analyst estimates of $4.73 billion. Oscar Health had a return on equity of 44.96% and a net margin of 3.60%.Oscar Health’s revenue was up 70.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.89) earnings per share.

Here are the key takeaways from Oscar Health’s conference call:

• Strong profitability and raised outlook: Oscar reported $1.1 billion in first-half earnings from operations and $1 billion in net income. Management raised full-year earnings-from-operations guidance by $250 million to $500 million–$700 million while maintaining its revenue outlook.
• Membership and operating metrics improved materially: Effectuated membership increased 46% year over year to 2.96 million, revenue rose 70% to $4.9 billion, and second-quarter MLR improved nearly 12 points to 79.2%. The SG&A ratio fell 450 basis points to a record-low 14.2%.
• Favorable medical trends provide potential upside: Inpatient, professional, and pharmacy utilization were favorable, while outpatient utilization was elevated but stable. Early 2026 morbidity data was better than pricing assumptions, although Oscar has not fully reflected that potential benefit in its guidance.
• Technology and AI are driving efficiency: Oscar said its AI-enabled claims, pharmacy, care-navigation, and member-support tools are reducing costs and improving productivity. The company expects its pharmacy analytics and related initiatives to generate tens of millions of dollars in annual savings and sees additional SG&A leverage ahead.
• Enrollment churn is expected to increase in the second half: CMS eligibility and program-integrity reviews are expected to produce disenrollments that were delayed from the second quarter, with churn potentially approaching twice the previously expected 1%–2% monthly rate. Management said the financial impact is included in guidance and primarily reflects timing rather than a fundamental change in retention.

Oscar Health Stock Performance

Shares of NYSE:OSCR traded up $1.39 during mid-day trading on Friday, reaching $27.93. 10,468,402 shares of the company traded hands, compared to its average volume of 4,846,594. The company’s 50 day moving average price is $28.93 and its 200-day moving average price is $20.37. The firm has a market cap of $8.42 billion, a PE ratio of 19.95, a PEG ratio of 1.35 and a beta of 2.36. Oscar Health has a 52 week low of $10.69 and a 52 week high of $33.10. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.11 and a quick ratio of 1.11.

Insider Activity at Oscar Health

In other Oscar Health news, CEO Mark T. Bertolini sold 624,244 shares of Oscar Health stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $28.48, for a total transaction of $17,778,469.12. Following the transaction, the chief executive officer owned 7,751,570 shares of the company’s stock, valued at $220,764,713.60. The trade was a 7.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Janet Liang sold 12,475 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $21.94, for a total transaction of $273,701.50. Following the completion of the transaction, the insider owned 259,057 shares of the company’s stock, valued at approximately $5,683,710.58. The trade was a 4.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 3,662,466 shares of company stock worth $105,145,815 in the last 90 days. Insiders own 22.64% of the company’s stock.

Institutional Investors Weigh In On Oscar Health

Institutional investors and hedge funds have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. boosted its stake in shares of Oscar Health by 11.0% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 9,217,816 shares of the company’s stock worth $132,461,000 after acquiring an additional 910,320 shares during the period. Morgan Stanley raised its stake in Oscar Health by 42.8% during the 4th quarter. Morgan Stanley now owns 6,814,046 shares of the company’s stock valued at $97,918,000 after purchasing an additional 2,043,758 shares during the period. Thrive Capital Management LLC raised its stake in Oscar Health by 33.4% during the 4th quarter. Thrive Capital Management LLC now owns 6,343,617 shares of the company’s stock valued at $85,258,000 after purchasing an additional 1,588,395 shares during the period. State Street Corp lifted its holdings in Oscar Health by 1.1% in the 4th quarter. State Street Corp now owns 5,186,570 shares of the company’s stock worth $74,531,000 after purchasing an additional 54,721 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Oscar Health by 0.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 3,718,765 shares of the company’s stock worth $70,400,000 after purchasing an additional 31,785 shares during the period. 75.70% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have issued reports on OSCR shares. Piper Sandler reissued an “overweight” rating and issued a $36.00 target price on shares of Oscar Health in a research report on Tuesday, July 28th. Weiss Ratings raised shares of Oscar Health from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, July 10th. Wolfe Research started coverage on shares of Oscar Health in a research note on Tuesday, May 5th. They issued a “peer perform” rating on the stock. Wall Street Zen raised shares of Oscar Health from a “buy” rating to a “strong-buy” rating in a report on Sunday, June 14th. Finally, Wells Fargo & Company set a $20.00 target price on shares of Oscar Health and gave the company an “equal weight” rating in a report on Thursday, June 4th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $24.00.

Key Stories Impacting Oscar Health

Here are the key news stories impacting Oscar Health this week:

• Positive Sentiment: Substantial earnings and revenue beat: Oscar reported quarterly EPS of $1.10, versus the $0.40–$0.43 analyst consensus, compared with a $0.89 loss in the year-ago quarter. Revenue rose 70.4% to $4.88 billion, exceeding estimates of approximately $4.73 billion. Oscar Health Inc. Q2 Earnings Beat Estimates
• Positive Sentiment: Profitability improved sharply: The insurer generated approximately $361 million of second-quarter profit and more than $1 billion in net income during the first half, helped by membership growth and easing medical costs. Oscar Health Reports Another Big Profit
• Positive Sentiment: Full-year outlook was raised: Oscar increased its 2026 revenue forecast to $18.7 billion–$19.0 billion, above the roughly $18.6 billion consensus estimate, and indicated $500 million–$700 million in earnings from operations with an 81.5%–82.5% medical-loss-ratio target. Oscar Health Signals 2026 Earnings Outlook
• Neutral Sentiment: The results reinforce Oscar’s improving profit-turnaround story, with technology and operational execution remaining important to managing a changing customer base. Oscar Health 2026 Profit Turnaround
• Negative Sentiment: Churn outlook pressured the shares: Management’s forecast for elevated member churn raised concerns about retention, future enrollment growth and whether the unusually strong earnings can be sustained. That concern reportedly outweighed the quarterly beat and guidance increase. Oscar Health Falls as Churn Forecast Overshadows Q2 Beat

Oscar Health Company Profile

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.